A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
A phase 2 trial of Purinostat in peripheral T-cell lymphomas, run by Chengdu Zenitar Biomedical Technology Co., Ltd, active and no longer recruiting.
Overview
A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma is a phase 2 interventional study registered as NCT06485219 by Chengdu Zenitar Biomedical Technology Co., Ltd, with 50 participants enrolled, started 2024-04-14 and due to reach its primary completion in 2026-06-30. Interventions recorded: 11.2 mg/m2 Purinostat Mesylate and 15 mg/m2 Purinostat Mesylate.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors
Shares Purinostat, Chengdu Zenitar Biomedical Technology and the tag pipeline.
- TrialPurinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Shares Purinostat, Chengdu Zenitar Biomedical Technology and the tag pipeline.
- TrialStudy of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
- TrialPhase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
Shares Chengdu Zenitar Biomedical Technology and the tag pipeline.
- TrialA Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
- TrialA Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialA Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialStudy to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.